Objective: To report the findings in 27 patients with
peripheral neuropathy (21 with lower extremity sensory
impairment associated with diabetic peripheral neuropathy
and 6 with other causes). who received treatment with
monochromatic near-infrared photoenergy (890 nm)
delivered by the Anodyne Therapy System (ATS).
Methods: All enrolled patients exhibited abnormal
sensory perception (either hyperesthesia or hypoesthesia)
based on a qualifying examination with the Neurometer
CPT (current perception threshold) (baseline CPT). The
patients received 10 ATS treatments (each lasting 40 minutes)
during a 2-week period and then underwent CPT
retesting to determine the extent of improvement of sensory
impairment in myelinated and unmyelinated sensory
fibers of the peroneal nerve.
Results: All patients obtained improvement in sensory
impairment in comparison with baseline CPT measures.
and 16 of the 27 patients achieved normal sensory
responses in all nerve fiber subpopulations. Ten patients
had been tested previously (initial CPT) and did not exhibit
spontaneous improvement in sensory impairment during
a mean period of 27 months before baseline CPT. After
receiving the ATS treatments. however. this group of
patients showed improvement in comparison with both
initial CPT results and baseline CPT.
Conclusion: On the basis of the data from this study.
the ATS seems to be a safe and effective treatment to
improve sensory impairment associated with peripheral
neuropathy due to diabetes